品牌 | 货号 | 包装单位 | 货期 | CAS | 产品名称 | 质量规格 | 单价(¥) | 购买数量 |
---|---|---|---|---|---|---|---|---|
阿拉丁 | P125494-5mg | 5mg | 现货 | 391210-10-9 |
PD0325901,MEK1 / 2的抑制剂 PD0325901 |
Moligand™, ≥99% |
|
|
阿拉丁 | P125494-25mg | 25mg | 现货 | 391210-10-9 |
PD0325901,MEK1 / 2的抑制剂 PD0325901 |
Moligand™, ≥99% |
|
|
阿拉丁 | P125494-100mg | 100mg | 现货 | 391210-10-9 |
PD0325901,MEK1 / 2的抑制剂 PD0325901 |
Moligand™, ≥99% |
|
|
阿拉丁 | M409191-1ml | 1ml | 期货,请咨询 | 391210-10-9 |
Mirdametinib (PD0325901) Mirdametinib (PD0325901) |
Moligand™, 10mM in DMSO |
|
|
阿拉丁 | P125494-1mg | 1mg | 现货 | 391210-10-9 |
PD0325901,MEK1 / 2的抑制剂 PD0325901 |
Moligand™, ≥99% |
|
|
麦克林 | P864378-5mg | 5mg | 现货 | 391210-10-9 |
PD0325901 PD0325901 |
≥99% |
|
|
罗恩 | R028681-25mg | 25mg | 5~7个工作日 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
罗恩 | R028681-5mg | 5mg | 5~7个工作日 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
罗恩 | R028681-100mg | 100mg | 5~7个工作日 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
MARY | MR139792-100mg | 100mg | 订前咨询 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
MARY | MR139792-25mg | 25mg | 订前咨询 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
MARY | MR139792-5mg | 5mg | 订前咨询 | 391210-10-9 |
PD0325901 PD0325901 |
99% |
|
|
源叶 | S46746-5mg | 5mg | 现货 | 391210-10-9 |
PD0325901 PD0325901 |
≥99% |
|
|
源叶 | S46746-25mg | 25mg | 现货 | 391210-10-9 |
PD0325901 PD0325901 |
≥99% |
|
|
源叶 | S46746-100mg | 100mg | 现货 | 391210-10-9 |
PD0325901 PD0325901 |
≥99% |
|
|
源叶 | T98213-1ml | 1ml | 期货,请咨询 | 391210-10-9 |
Mirdametinib (PD0325901) Mirdametinib (PD0325901) |
10mM in DMSO |
|
|
毕得 | BD222618-5mg | 5mg | 现货 | 391210-10-9 |
N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2... (R)-N-(2,3-Dihydroxypropoxy)... |
98% |
|
|
毕得 | BD222618-100mg | 100mg | 现货 | 391210-10-9 |
N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2... (R)-N-(2,3-Dihydroxypropoxy)... |
98% |
|
|
毕得 | BD222618-250mg | 250mg | 现货 | 391210-10-9 |
N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2... (R)-N-(2,3-Dihydroxypropoxy)... |
98% |
|
|
毕得 | BD222618-1g | 1g | 现货 | 391210-10-9 |
N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2... (R)-N-(2,3-Dihydroxypropoxy)... |
98% |
|
|